Grant: Master's Award: Canada Graduate Research Scholarships - Master's program
University of Alberta
$27,000.00
Alternative Surfactant Administration Routes to Improve Outcomes in Preterm Infants
FY 2025-26
Summary
Respiratory distress syndrome (RDS) affects up to 65% of infants born before 32 weeks because they lack adequate surfactant, leading to alveolar collapse and poor gas exchange. Traditional treatment with intubation following laryngoscopy and mechanical ventilation increases the risk of lung injury. Minimally invasive surfactant therapy (MIST) reduces these risks but still requires a laryngoscope, which can cause slow heart rate, hypoxia, and intraventricular hemorrhage (IVH). Surfactant delivery through a supraglottic airway device (SAD) avoids these complications by removing the need for a laryngoscope, offering a faster, less traumatic method that allows infant to breathe on their own. Early studies show SAD use is feasible in infants 32 weeks gestation and older, infants 26-32 weeks’ having previously been excluded due to limited SAD sizes. Though new SADs are now suitable for infants 26 weeks gestation, their safety, feasibility, and effectiveness in this group remain unstudied. This pilot trial will evaluate SAD-guided surfactant administration in 40 infants born at 26-32 weeks’ gestation, less than 48 hours old, and diagnosed with RDS. Infants will be randomized 1:1 to receive surfactant via SAD or MIST, and parameters such as heart rate and oxygen saturation will be recorded. I hypothesize that SAD will reduce incidences of hypoxia, slow heart rate, and IVH as compared to MIST. My role includes obtaining informed consent, collecting and entering clinical data into a REDcap database, collaborating with a statistician, and sharing the work. This study may support SAD as a safer, less invasive alternative to MIST, reducing heart rate, hypoxia, and IVH, and improving outcomes for vulnerable preterm infants and their families.
Department
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
573194
Name
Persad Rohan K
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Alternative Surfactant Administration Routes to Improve Outcomes in Preterm Infants
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Broncho-Pulmonary Dysplasia; Intraventricular Hemorrhage; Laryngoscope; Mechanical Ventilation; Minimally Invasive Surfactant Administration (Mist); Neonatal; Respiratory Distress Syndrome; Supraglottic Airway Device (Sad); Surfactant Administration; Very Preterm
Abstract
Respiratory distress syndrome (RDS) affects up to 65% of infants born before 32 weeks because they lack adequate surfactant, leading to alveolar collapse and poor gas exchange. Traditional treatment with intubation following laryngoscopy and mechanical ventilation increases the risk of lung injury. Minimally invasive surfactant therapy (MIST) reduces these risks but still requires a laryngoscope, which can cause slow heart rate, hypoxia, and intraventricular hemorrhage (IVH). Surfactant delivery through a supraglottic airway device (SAD) avoids these complications by removing the need for a laryngoscope, offering a faster, less traumatic method that allows infant to breathe on their own. Early studies show SAD use is feasible in infants 32 weeks gestation and older, infants 26-32 weeks’ having previously been excluded due to limited SAD sizes. Though new SADs are now suitable for infants 26 weeks gestation, their safety, feasibility, and effectiveness in this group remain unstudied. This pilot trial will evaluate SAD-guided surfactant administration in 40 infants born at 26-32 weeks’ gestation, less than 48 hours old, and diagnosed with RDS. Infants will be randomized 1:1 to receive surfactant via SAD or MIST, and parameters such as heart rate and oxygen saturation will be recorded. I hypothesize that SAD will reduce incidences of hypoxia, slow heart rate, and IVH as compared to MIST. My role includes obtaining informed consent, collecting and entering clinical data into a REDcap database, collaborating with a statistician, and sharing the work. This study may support SAD as a safer, less invasive alternative to MIST, reducing heart rate, hypoxia, and IVH, and improving outcomes for vulnerable preterm infants and their families.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Persad, Rohan K
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~